Verteporfin protects against Th17 cell-mediated EAE independently of YAP inhibition.

Paulin BrosinskyHanna LeisterNan ChengXaralabos VarelasAlexander Visekruna Maik Luu

Published in: European journal of immunology (2022)

The known YAP inhibitor verteporfin is capable of repressing IL-17A production in Th17 cells. However, this effect is mediated independently of YAP and can ameliorate Th17-mediated experimental autoimmune encephalomyelitis (EAE) upon in vivo administration. The data suggest verteprofin's mode of action for the design of novel therapeutic autoimmune disease intervention.

Keyphrases

randomized controlled trial
induced apoptosis
multiple sclerosis
single cell
stem cells
oxidative stress
machine learning
bone marrow
endoplasmic reticulum stress
artificial intelligence